MAY - 2023LIFE SCIENCES REVIEW7To successfully combat diseases and promote healthier lifestyles, it is imperative that various fields within biotechnology and biomanufacturing be strengthened and further developed. The emergence of next-generation biomanufacturing services has allowed for the production of a diverse range of products with superior quality compared to their first-generation counterparts.Traditionally, biomanufacturing solutions relied on plasmid DNA as a vector for gene therapy. However, recent advancements in DNA synthesis technology have given rise to a new biomanufacturing solution known as dbDNA (double-stranded DNA). This innovative technology has the potential to revolutionize biomanufacturing due to its rapid manufacturing timeline. Ongoing research and development efforts surrounding this linear molecule are anticipated to optimize its use for producing a wide array of biologics. With the ability to generate proteins and antibodies, this emerging technology enhances the speed, purity, and adaptability of specific proteins and antibodies, surpassing the limitations of traditional cell-based systems.In the United States, the utilization of dbDNA has experienced a consistent upward trend in recent years, with projections estimating its value to reach USD 30.7 billion by 2026, representing a compound annual growth rate of 20.0 percent. The expansion of biologics production, the rising acceptance of gene therapies, and the advancement of personalized medicine are the primary factors propelling the growth of the dbDNA market within the region.In this edition of Life Sciences Review, we present biomanufacturing solutions at the revolutionary forefront improving the sustainability of the genetic medicines market. Featured company TAAV Biomanufacturing Solutions produces synthetic DNA, dbDNATM, as an alternative to plasmid DNA for the manufacture of Adeno-Associated Virus (AAV). The company's synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV, and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.The magazine also includes insightful opinions of Nick Thomson, Senior Director, Chemical Research and Development, Pfizer Inc., and Carlos Pedraza, Ph.D., Director of CNS Biology, Alkermes, emphasizing the importance of ensuring the safety and efficacy of biologics. We hope these valuable insights from industry leaders featured in this edition will assist you in making informed decisions for your businesses.Let us know your thoughts.EDITORIALInnovating Biomanufacturing: The Emergence of dbDNA TechnologyCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com MAY - 2023, Vol 04, Issue - 18 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersAlex FloresDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsXavier YoungClara Matthew
< Page 6 | Page 8 >